Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Candel Therapeutics Inc (NASDAQ: CADL) closed the day trading at $5.96 down -3.40% from the previous closing price of $6.17. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 0.64 million shares were traded. CADL stock price reached its highest trading level at $6.175 during the session, while it also had its lowest trading level at $5.9.
Ratios:
For a better understanding of CADL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.64 and its Current Ratio is at 4.64. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.02.
On February 20, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $25.
On February 19, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.Canaccord Genuity initiated its Buy rating on February 19, 2025, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 28 ’25 when Nichols William Garrett sold 937 shares for $6.98 per share. The transaction valued at 6,540 led to the insider holds 52,493 shares of the business.
Nichols William Garrett sold 781 shares of CADL for $3,936 on Jun 30 ’25. The Chief Medical Officer now owns 52,493 shares after completing the transaction at $5.04 per share. On Jun 30 ’25, another insider, WILLIAM GARRETT NICHOLS, who serves as the Officer of the company, bought 3,593 shares for $4.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CADL now has a Market Capitalization of 298612096 and an Enterprise Value of 217359968.
Stock Price History:
The Beta on a monthly basis for CADL is -0.87, which has changed by 0.08561015 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, CADL has reached a high of $14.60, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 2.77%, while the 200-Day Moving Average is calculated to be -6.39%.
Shares Statistics:
Over the past 3-months, CADL traded about 942.00K shares per day on average, while over the past 10 days, CADL traded about 643840 shares per day. A total of 49.25M shares are outstanding, with a floating share count of 36.70M. Insiders hold about 31.18% of the company’s shares, while institutions hold 36.23% stake in the company. Shares short for CADL as of 1752537600 were 6555372 with a Short Ratio of 6.96, compared to 1749772800 on 6259547. Therefore, it implies a Short% of Shares Outstanding of 6555372 and a Short% of Float of 16.950001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 2 analysts. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.12 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.53 and -$0.77 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.62, with 1.0 analysts recommending between -$0.62 and -$0.62.
